Business Context and Reporting Period
Company: Vyome Holdings, Inc. (Trading Symbol: HIND)
Filing Type: Form 8-K (Current Report)
Date of Report: February 13, 2026
Reporting Period: This filing covers a specific event on February 13, 2026, rather than a standard financial quarter or fiscal year. The Company is a Delaware corporation headquartered in Cambridge, MA, focused on the development of drug candidates, specifically VT-1953 for malignant fungating wounds.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a disclosure of presentation materials rather than a financial results report.
Material Changes
Regulation FD Disclosure: The Company disclosed that representatives intend to present information at investor conferences. The core material change is the furnishing of "VT-1953 Phase 2 Data Presentation" (Exhibit 99.1), which is incorporated by reference into this report.
Guidance, Outlook, and Risks
Outlook and Forward-Looking Statements: The filing contains forward-looking statements regarding:
- Development of drug candidates, including clinical trial timing and regulatory submissions.
- Business strategy and future operating results.
- Liquidity and capital resources outlook.
- Total addressable market for malignant fungating wounds in the U.S.
- Estimated peak annual net sales for VT-1953.
Risks and Contingencies: The Company highlights significant risks that could cause actual results to differ from expectations, including:
- Ability to raise capital to fund continuing operations.
- Protection of intellectual property rights and potential litigation.
- Competition from other providers.
- Ability to develop and commercialize VT-1953.
- Changes in government regulation.
Unusual Items: The information in Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. The Company undertakes no obligation to update this information.
Investor Verification Checklist
- Review Exhibit 99.1 (VT-1953 Phase 2 Data Presentation) for specific clinical data and sales estimates referenced in this filing.
- Verify the Company's current cash position and runway in the most recent 10-Q or 10-K, as this 8-K does not contain liquidity figures.
- Monitor upcoming investor conference presentations for updates on the VT-1953 development timeline.
- Assess the status of capital raising efforts given the explicit risk disclosure regarding funding operations.